Download video

Realizing the Potential of TYK2 Inhibition to Address the Burden of Psoriasis

22 views

PeerView CME

12 days ago

Realizing the Potential of TYK2 Inhibition to Address the Burden of Psoriasis

Realizing the Potential of TYK2 Inhibition to Address the Burden of Psoriasis

Patient-reported outcomes of mevrometostat and enzalutamide in mCRPC
1:52
Patient-reported outcomes of mevrometostat and enzalutamide in mCRPC
by VJOncology
Update From AACR-NCI-EORTC: PYNNACLE phase 2 study
6:27
Update From AACR-NCI-EORTC: PYNNACLE phase 2 study
by COR2ED The Heart of Medical Education
Cancer Found with SecondReadAI
0:48
Cancer Found with SecondReadAI
by Rezolut
TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors
1:10
TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors
by VJOncology
Exploring Predictive Biomarkers and ERK1\/2 Phosphorylation: A New Horizon in Glioblastoma Treatment
34:15
Exploring Predictive Biomarkers and ERK1\/2 Phosphorylation: A New Horizon in Glioblastoma Treatment
by InsideScientific
Recent advances in precision oncology and future implications
4:12
Recent advances in precision oncology and future implications
by COR2ED The Heart of Medical Education
Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resect...
3:31
Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resect...
by ecancer
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
0:52
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
Clinical Trials for Pancreatic Cancer
21:15
Clinical Trials for Pancreatic Cancer
by Let's Win Pancreatic Cancer
Biomarkers in ILD
8:22
Biomarkers in ILD
by RheumNow
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
9:03
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
by GU Oncology Now
Risk Identification Part 2
1:47:00
Risk Identification Part 2
by PharmaIdiots
9700\/JUNE22\/52 Q2 EXPLAINED
13:00
9700\/JUNE22\/52 Q2 EXPLAINED
by Dr Saira Biology
Evaluating the emerging role elraglusib as a treatment option in mPDCAC
1:10
Evaluating the emerging role elraglusib as a treatment option in mPDCAC
by VJOncology
Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
1:23
Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
by VJOncology
Topoisomerase Inhibitors Types of AntiCancer Drugs ; Examples, Uses, Mechanism of action
2:48
Topoisomerase Inhibitors Types of AntiCancer Drugs ; Examples, Uses, Mechanism of action
by MBBS NAIJA
Ruxolitinib Elicits Few Adverse Effects
2:01
Ruxolitinib Elicits Few Adverse Effects
by Institute for Myeloma \& Bone Cancer Research, IMBCR
ROAR study shows promising results for non-metastatic prostate cancer patients with rucaparib
3:29
ROAR study shows promising results for non-metastatic prostate cancer patients with rucaparib
by VJOncology
RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
1:33
RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
by VJOncology